In light of today's decision to relocate the European Medicines Agency to Amsterdam because of the UK's decision to leave the European Union, MedCity has issued the below statement.
Sarah Haywood, CEO at MedCity, the life sciences cluster organisation for London and the Greater South East, said:
“Whilst it is disappointing that the European Medicines Agency is relocating to Amsterdam after 22 years in London, we must recognise the important role our domestic regulator, the MHRA, makes and will continue to make to enable access to new medicines and products.
“Now we must focus on limiting the impact of the relocation by ensuring our regulation system is aligned with the EU, and we are working with the Mayor of London to reduce any disruption for researchers and companies, and, ultimately, patients.
“With over 1300 life sciences companies, world-class teaching hospitals, a strong pharma pipeline, and two of the world’s top 10 universities, I am confident that London will continue to thrive as a centre of research and innovation.”